TargetCyclin-dependent kinase 3(Homo sapiens (Human))
University Of Nebraska Medical Center
Curated by ChEMBL
University Of Nebraska Medical Center
Curated by ChEMBL
Affinity DataKi: >1.00E+3nMAssay Description:Inhibition of CDK3 (unknown origin)More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3(Homo sapiens (Human))
University Of Nebraska Medical Center
Curated by ChEMBL
University Of Nebraska Medical Center
Curated by ChEMBL
Affinity DataIC50: 0.800nMAssay Description:Inhibition of CDK3 (unknown origin) by kinase selectivity assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 0.940nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 1.70nMAssay Description:Inhibition of human CDK3/cyclin-E using histone H1 as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:Inhibition of CDK3/cyclin E (unknown origin)More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 2.10nMAssay Description:Inhibition of human CDK3/cyclin-E using histone H1 as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 2.10nMAssay Description:Inhibition of human CDK3/cyclin-E using histone H1 as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 2.80nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 2.90nMAssay Description:Inhibition of human CDK3/cyclin-E using histone H1 as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:Inhibition of recombinant human full length C-terminal His6-tagged CDK3/N-terminal GST-tagged cyclin E expressed in baculovirus infected Sf21 insect ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 4nMAssay Description:Inhibition of CDK3/Cyclin E (unknown origin)-mediated phosphorylation of peptide substrate incubated for 15 mins prior to substrate addition measured...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 5nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3(Homo sapiens (Human))
University Of Nebraska Medical Center
Curated by ChEMBL
University Of Nebraska Medical Center
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of CDK3 (unknown origin) expressed in baculovirus-infected Sf9 insect cellsMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 6nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 6nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3(Homo sapiens (Human))
University Of Nebraska Medical Center
Curated by ChEMBL
University Of Nebraska Medical Center
Curated by ChEMBL
Affinity DataIC50: 6.90nMAssay Description:Inhibition of CDK3/Cyclin EMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 8nMAssay Description:Inhibition of C-terminal His6-tagged human CDK3/N-terminal GST-tagged human cyclin EMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 8nMAssay Description:Inhibition of recombinant human full-length C-terminal His6-tagged CDK3/full-length human N-terminal GST-tagged Cyclin E expressed in baculovirus inf...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 8nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 9nMAssay Description:Inhibition of in vitro kinase activity of purified CDKs.More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 9nMAssay Description:Inhibition of recombinant human full-length C-terminal His6-tagged CDK3/full-length human N-terminal GST-tagged Cyclin E expressed in baculovirus inf...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 9.90nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 10nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 10nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 11nMAssay Description:Inhibition of human CDK3/cyclinE using Histone H1 as substrate incubated for 2 hrs by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 13nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 18nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3(Homo sapiens (Human))
University Of Nebraska Medical Center
Curated by ChEMBL
University Of Nebraska Medical Center
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of CDK3 (unknown origin) in presence of 5 mM ATPMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 23nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 23nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3(Homo sapiens (Human))
University Of Nebraska Medical Center
Curated by ChEMBL
University Of Nebraska Medical Center
Curated by ChEMBL
Affinity DataIC50: 23nMAssay Description:Inhibition of CDK3 (unknown origin) in presence of 5 mM ATPMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 28nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 29nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3(Homo sapiens (Human))
University Of Nebraska Medical Center
Curated by ChEMBL
University Of Nebraska Medical Center
Curated by ChEMBL
Affinity DataIC50: 29nMAssay Description:Inhibition of CDK3 (unknown origin)More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 34nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 38nMAssay Description:Inhibition of CDK3/Cyclin E (unknown origin)-mediated phosphorylation of peptide substrate incubated for 15 mins prior to substrate addition measured...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 51nMAssay Description:Inhibition of human CDK3/cyclinE using Histone H1 as substrate incubated for 2 hrs by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 54nMAssay Description:Inhibition of full length human recombinant CDK3/Cyclin E using histone H1 as substrate incubated for 40 mins in presence of [gamma-33ATP] by radiome...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 57nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3(Homo sapiens (Human))
University Of Nebraska Medical Center
Curated by ChEMBL
University Of Nebraska Medical Center
Curated by ChEMBL
Affinity DataIC50: 58nMAssay Description:Inhibition of CDK3 (unknown origin)More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 58nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 59nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 73nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 75nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3(Homo sapiens (Human))
University Of Nebraska Medical Center
Curated by ChEMBL
University Of Nebraska Medical Center
Curated by ChEMBL
Affinity DataIC50: 84nMAssay Description:Inhibition of CDK3 (unknown origin) in presence of 5 mM ATPMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 94nMAssay Description:Inhibition of recombinant human CDK3/cyclin E expressed in baculovirus infected Sf9 insect cells after 80 mins in presence of [33P]ATP by microbeta s...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 96nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 105nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 106nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 3/G1/S-specific cyclin-E1(Homo sapiens (Human))
G1 Therapeutics
US Patent
G1 Therapeutics
US Patent
Affinity DataIC50: 113nMAssay Description:Inhibition of CDK3/cyclin E1 (unknown origin) using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition ...More data for this Ligand-Target Pair